Pharvaris(PHVS)
Netherlands - LeidenBiotechnology
Focus: Pharvaris is a public-stage biotechnology company focused on small-molecule therapeutics, headquartered in Leiden, Netherlands, with a concentrated pipeline in angioedema and related conditions.
Profile data last refreshed 12h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
3+2 this month
Stable — net +2 jobs in 30d
3 added, 1 removed. Backfill posture.
Should You Work at Pharvaris?
AI assessmentEarly-stage public biotech with strong late-stage pipeline but limited hiring and no approved drugs; best for specialists willing to bet on Phase 3 success with modest near-term job security.
Why Work Here
- Lead program (Deucrictibant) in Phase 3 for Hereditary Angioedema with multiple trials active, offering exposure to late-stage drug development
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Late-stage
5 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Deucrictibant
Hereditary AngioedemaClinical Trials (1)
NCT04618211Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
Phase 2Help build intelligence for Pharvaris
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.